Cargando…

LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling

Ewing sarcoma (ES) is an aggressive bone and soft tissue tumor of putative stem cell origin that predominantly occurs in children and young adults. Although most patients with localized ES can be cured with intensive therapy, the clinical course is variable and up to one third of patients relapse fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Scannell, Christopher A., Pedersen, Elisabeth A., Mosher, Jack T., Krook, Melanie Anne, Nicholls, Lauren A., Wilky, Breelyn A., Loeb, David M., Lawlor, Elizabeth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625903/
https://www.ncbi.nlm.nih.gov/pubmed/23596566
http://dx.doi.org/10.3389/fonc.2013.00081
_version_ 1782266139468890112
author Scannell, Christopher A.
Pedersen, Elisabeth A.
Mosher, Jack T.
Krook, Melanie Anne
Nicholls, Lauren A.
Wilky, Breelyn A.
Loeb, David M.
Lawlor, Elizabeth R.
author_facet Scannell, Christopher A.
Pedersen, Elisabeth A.
Mosher, Jack T.
Krook, Melanie Anne
Nicholls, Lauren A.
Wilky, Breelyn A.
Loeb, David M.
Lawlor, Elizabeth R.
author_sort Scannell, Christopher A.
collection PubMed
description Ewing sarcoma (ES) is an aggressive bone and soft tissue tumor of putative stem cell origin that predominantly occurs in children and young adults. Although most patients with localized ES can be cured with intensive therapy, the clinical course is variable and up to one third of patients relapse following initial remission. Unfortunately, little is yet known about the biologic features that distinguish low-risk from high-risk disease or the mechanisms of ES disease progression. Recent reports have suggested that putative cancer stem cells exist in ES and may contribute to an aggressive phenotype. The cell surface receptor leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is a somatic stem cell marker that functions as an oncogene in several human cancers, most notably colorectal carcinoma. LGR5 is a receptor for the R-spondin (RSPO) family of ligands and RSPO-mediated activation of LGR5 potentiates Wnt/β-catenin signaling, contributing to stem cell proliferation and self-renewal. Given its presumed stem cell origin, we investigated whether LGR5 contributes to ES pathogenesis. We found that LGR5 is expressed by ES and that its expression is relatively increased in cells and tumors that display a more aggressive phenotype. In particular, LGR5 expression was increased in putative cancer stem cells. We also found that neural crest-derived stem cells express LGR5, raising the possibility that expression of LGR5 may be a feature of ES cells of origin. LGR5-high ES cells showed nuclear localization of β-catenin and robust activation of TCF reporter activity when exposed to Wnt ligand and this was potentiated by RSPO. However, modulation of LGR5 or exposure to RSPO had no impact on proliferation confirming that Wnt/β-catenin signaling in ES cells does not recapitulate signaling in epithelial cells. Together these studies show that the RSPO-LGR5-Wnt-β-catenin axis is present and active in ES and may contribute to tumor pathogenesis.
format Online
Article
Text
id pubmed-3625903
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-36259032013-04-17 LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling Scannell, Christopher A. Pedersen, Elisabeth A. Mosher, Jack T. Krook, Melanie Anne Nicholls, Lauren A. Wilky, Breelyn A. Loeb, David M. Lawlor, Elizabeth R. Front Oncol Oncology Ewing sarcoma (ES) is an aggressive bone and soft tissue tumor of putative stem cell origin that predominantly occurs in children and young adults. Although most patients with localized ES can be cured with intensive therapy, the clinical course is variable and up to one third of patients relapse following initial remission. Unfortunately, little is yet known about the biologic features that distinguish low-risk from high-risk disease or the mechanisms of ES disease progression. Recent reports have suggested that putative cancer stem cells exist in ES and may contribute to an aggressive phenotype. The cell surface receptor leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is a somatic stem cell marker that functions as an oncogene in several human cancers, most notably colorectal carcinoma. LGR5 is a receptor for the R-spondin (RSPO) family of ligands and RSPO-mediated activation of LGR5 potentiates Wnt/β-catenin signaling, contributing to stem cell proliferation and self-renewal. Given its presumed stem cell origin, we investigated whether LGR5 contributes to ES pathogenesis. We found that LGR5 is expressed by ES and that its expression is relatively increased in cells and tumors that display a more aggressive phenotype. In particular, LGR5 expression was increased in putative cancer stem cells. We also found that neural crest-derived stem cells express LGR5, raising the possibility that expression of LGR5 may be a feature of ES cells of origin. LGR5-high ES cells showed nuclear localization of β-catenin and robust activation of TCF reporter activity when exposed to Wnt ligand and this was potentiated by RSPO. However, modulation of LGR5 or exposure to RSPO had no impact on proliferation confirming that Wnt/β-catenin signaling in ES cells does not recapitulate signaling in epithelial cells. Together these studies show that the RSPO-LGR5-Wnt-β-catenin axis is present and active in ES and may contribute to tumor pathogenesis. Frontiers Media S.A. 2013-04-15 /pmc/articles/PMC3625903/ /pubmed/23596566 http://dx.doi.org/10.3389/fonc.2013.00081 Text en Copyright © 2013 Scannell, Pedersen, Mosher, Krook, Nicholls, Wilky, Loeb and Lawlor. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Oncology
Scannell, Christopher A.
Pedersen, Elisabeth A.
Mosher, Jack T.
Krook, Melanie Anne
Nicholls, Lauren A.
Wilky, Breelyn A.
Loeb, David M.
Lawlor, Elizabeth R.
LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling
title LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling
title_full LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling
title_fullStr LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling
title_full_unstemmed LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling
title_short LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling
title_sort lgr5 is expressed by ewing sarcoma and potentiates wnt/β-catenin signaling
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625903/
https://www.ncbi.nlm.nih.gov/pubmed/23596566
http://dx.doi.org/10.3389/fonc.2013.00081
work_keys_str_mv AT scannellchristophera lgr5isexpressedbyewingsarcomaandpotentiateswntbcateninsignaling
AT pedersenelisabetha lgr5isexpressedbyewingsarcomaandpotentiateswntbcateninsignaling
AT mosherjackt lgr5isexpressedbyewingsarcomaandpotentiateswntbcateninsignaling
AT krookmelanieanne lgr5isexpressedbyewingsarcomaandpotentiateswntbcateninsignaling
AT nichollslaurena lgr5isexpressedbyewingsarcomaandpotentiateswntbcateninsignaling
AT wilkybreelyna lgr5isexpressedbyewingsarcomaandpotentiateswntbcateninsignaling
AT loebdavidm lgr5isexpressedbyewingsarcomaandpotentiateswntbcateninsignaling
AT lawlorelizabethr lgr5isexpressedbyewingsarcomaandpotentiateswntbcateninsignaling